Clinical trials: Hepatitis C
Hepatitis D, Hepatitis C
Evaluation of Patients With Liver Disease
The proposed study aims to evaluate, investigate, and follow-up patients suffering from acute and chronic liver disease. The study will focus on understanding diseases affecting the liver.
- Conditions
- Hepatitis D, Hepatitis C, Hepatitis B, Liver Disease
- Trial name
- NCT00001971
- Where
- United States
- Volunteers
- 8,050 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Metabolic Associated Fatty Liver Disease, Metabolic Associated Steatotic Liver Disease
Evaluation of Non-Invasive Tests for Metabolic Liver Disease
The Non-Invasive Biomarkers for Metabolic Liver Disease (NIMBLE) study is a comprehensive, multi-year collaborative effort to standardize, validate and advance the regulatory qualification of blood- and imaging-based biomarkers…
- Conditions
- Metabolic Associated Fatty Liver Disease, Metabolic Associated Steatotic Liver Disease, Cirrhosis, Liver, NASH
- Trial name
- NIMBLE (NCT07122700)
- Where
- 4 sites in United States
- Volunteers
- 400 people
- Sponsor
- Foundation for the National Institutes of Health
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)
This study will test a Regeneron study drug called ALN-CIDEB to find out whether it may help treat a liver disease called MASH. In this study, researchers are looking at the effect of ALN-CIDEB on reducing liver fat, liver…
- Trial name
- NCT07631637
- Testing
- ALN-CIDEB
- Where
- 16 sites in United States, Puerto Rico
- Volunteers
- 150 people
- Sponsor
- Regeneron Pharmaceuticals
Diabetes Mellitus, Hepatitis C, Chronic
People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents
Background: Chronic hepatitis C infects the liver. It may scar the liver. This is called cirrhosis and may lead to liver cancer or death. Current chronic hepatitis C treatments cure most people.
- Conditions
- Diabetes Mellitus, Hepatitis C, Chronic, Cardiovascular Diseases
- Trial name
- NCT03520660
- Testing
- Epclusa
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Liver Disease and Cirrhosis, Liver Cancer
"Constitution of a Biological Collection to Establish Preclinical Translational Models for the Study of Tumors and Chronic Liver Diseases".
Development of preclinical translational models for chronic liver tumors and diseases study, such as spheroids cultured in autologous medium and murine xenograft models to test the efficacy of new therapeutic strategies.
- Conditions
- Chronic Liver Disease and Cirrhosis, Liver Cancer, Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis
- Trial name
- LivMOD (NCT04690972)
- Testing
- Blood sample during surgery, Taking an additional biopsy, Blood sample during diagnostic test
- Where
- France
- Volunteers
- 800 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Chronic Hepatitis Delta Virus Infection
A Study to Assess Efficacy and Safety of HH-003 Injection in Subjects With Chronic Hepatitis Delta Virus Infection
This is a multicenter, randomized, controlled, open-label, Phase IIb study of HH-003 injection, HH-003 injection is a monoclonal antibody targeting Hepatitis B virus.
- Trial name
- NCT05861674
- Testing
- HH-003(20mg/kg), HH-003(10mg/kg), TAF
- Where
- 7 sites in China, Pakistan
- Volunteers
- 101 people
- Sponsor
- Huahui Health
Autoimmune Hepatitis
Belimumab in Autoimmune Hepatitis
Background: Autoimmune hepatitis (AIH) is a rare chronic and lifelong liver disease. Untreated, disease progresses to end-stage cirrhosis and the focus of therapy is with immunosuppression.
- Trial name
- BELief (NCT06381453)
- Testing
- Belimumab Auto-Injector [Benlysta]
- Where
- 6 sites in Canada
- Volunteers
- 48 people
- Sponsor
- University Health Network, Toronto
Chronic Hepatitis B Virus (HBV) Infection
A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)
This Phase 2, randomized, double-blind study will evaluate the clinical efficacy and safety of the combination therapy of BRII-179, BRII-835, plus PEG-IFNα compared to PEG-IFNα in adult participants with chronic HBV infection…
- Trial name
- NCT06650852
- Testing
- BRII-179, BRII-835 (VIR-2218), PEG-IFNα
- Where
- 14 sites in China
- Volunteers
- 250 people
- Sponsor
- Brii Biosciences Limited
Hepatitis A
Study on the Long-Term Persistence of Immunity Induced by Inactivated Hepatitis A Vaccine
This study is a single-center, open-label, controlled study. Its primary objective is to evaluate the 20-year persistence of immunity induced by the inactivated hepatitis A vaccine.
- Trial name
- NCT07889219
- Testing
- Healive®, Havrix®
- Where
- China
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Hepatitis B, Vaccination; Infection
The Immune Responses After Hepatitis B Revaccination Doses in a Young Cohort
This prospective cohort study aims to provide the evidence-based clinical guide to help decide the revaccination doses of hepatitis B vaccine that the high-risk young adults without hepatitis B seroprotective antibodies (anti-HBs…
- Conditions
- Hepatitis B, Vaccination; Infection, Preventable Disease, Vaccine
- Trial name
- IRHBRVD (NCT04970836)
- Testing
- recombinant hepatitis B vaccine
- Where
- Taiwan
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
For Treatment of Chronic Hepatitis B Virus Infection
Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)
This study will evaluate the efficacy and safety of the regimens containing BRII-179, BRII-835, and PEG-IFNα in adult participants with chronic hepatitis B virus (HBV) infection receiving nucleos(t)ide reverse transcriptase…
- Trial name
- NCT06491563
- Testing
- BRII-179, BRII-835 (VIR-2218), PEG-IFNα
- Where
- 12 sites in China
- Volunteers
- 150 people
- Sponsor
- Brii Biosciences Limited
Chronic Hepatitis B Virus
A Clinical Study of AHB-121 in Healthy Participants and Chronic Hepatitis B (CHB) Participants
This is a clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AHB-121 injection in healthy and chronic hepatitis B participants.
- Trial name
- NCT07884864
- Testing
- AHB-121
- Where
- China
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Ausper Biopharma Co., Ltd.
Hepatitis C, Opioid-Related Disorders
The Kentucky Viral Hepatitis Treatment Study
The overarching goal of the Kentucky Viral Hepatitis Treatment Project (KeY Treat) is to increase hepatitis C virus (HCV) treatment access and delivery in a rural Appalachian community, which is in the midst of the…
- Conditions
- Hepatitis C, Opioid-Related Disorders, Injection Drug Use
- Trial name
- KeY Treat (NCT03949764)
- Testing
- Sofosbuvir/velpatasvir (Epclusa®)
- Where
- United States
- Volunteers
- 380 people
- Sponsor
- Jennifer Havens
Chronic Hepatitis B
Functional Cure Rate of Peg-IFNα-2b Combined With TAF in HBeAg Negative CHB Patients
The study is aimed to explore the safety and efficacy of the pulse usage , comparing to continuous usage, of Peginterferon alfa-2b Injection (PEG IFN α-2b) Combined With tenofovir alafenamide (TAF) in treatment of naive chronic…
- Trial name
- NCT05490836
- Testing
- PEG IFN α-2b; TAF
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Huashan Hospital
Chronic Hepatitis B Virus Infection
Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients
This study will evaluate the efficacy and safety of PEG-IFNα alone or in combination with different dose levels of BRII-835 (VIR-2218) in participants with chronic hepatitis B virus (HBV) infection.
- Trial name
- NCT05970289
- Testing
- PEG-IFNα, BRII-835
- Where
- 28 sites in Australia, China and 3 more
- Volunteers
- 86 people
- Sponsor
- Brii Biosciences Limited
Hepatitis B
Decentralization of Hepatitis B Care in Sub-Saharan Africa: a Pilot Program in Ethiopia
The goal of this observational study is to study models of care for decentralized hepatitis B treatment in Ethiopia. Three different models of decentralized HBV care (standard model, simplified model, test-and-treat model) will…
- Trial name
- NCT06586983
- Testing
- Tenofovir Disoproxil Fumarate
- Where
- Ethiopia
- Volunteers
- 4,500 people
- Sponsor
- Oslo University Hospital
Hepatitis C, Chronic, Pregnancy; Infection
Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy
This is a multicenter, single arm study of Sofosbuvir/Velpatasvir (SOF/VEL) for treatment of chronic hepatitis C infection during pregnancy.
- Trial name
- STORC (NCT05140941)
- Testing
- Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet
- Where
- 9 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- Catherine Anne Chappell
Chronic Hepatitis B
A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB)
This is a study of sequential therapy with AHB-137 injection followed by TVAX-008 injection in participants living with Chronic Hepatitis B (CHB).
- Trial name
- NCT07876856
- Testing
- AHB-137, TVAX-008
- Volunteers
- 105 people
- Sponsor
- Ausper Biopharma Co., Ltd.
Cirrhosis
Deciphering the Mechanisms Involved in Microbial Translocation Across the Spectrum of HCV Associated Liver Fibrosis
Background: Hepatitis C infection (HCV) is a leading cause of liver disease. Normal bacteria from the intestines may spread to the liver and blood during liver disease. This is called bacterial translocation (BT).
- Trial name
- NCT02400216
- Testing
- dual cholate
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Hepatitis b, Women
Efficacy and Adverse Effects of Nucleoside Analogues (TDF/LDT) in Preventing Mother-to-child Transmission of HBV
Mother-to-Child-Transmission (MTCT) of HBV is the most important route in high endemic countries. Although active-passive immune prophylaxis is generally administrated to infants delivered by HBsAg positive women, there are a lot…
- Trial name
- NCT03181607
- Where
- China
- Volunteers
- 153 people
- Sponsor
- Xingfei Pan